TriangleNCT01168232 · OUTCOME
Overall Survival
Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.
- Measure
- MEDIAN
- Unit
- months
- Interval / dispersion
- 95% Confidence Interval
- Time frame
- From study entry to death or last contact, up to 5 years of follow-up.
What was measured
Overall survival is defined as the duration of time from study entry to time of death or the date of last contact.
Analysis population: Eligible and Treated Patients
Groups in this outcome
Ixabepilone
Ixabepilone administered at 40 mg/m2 IV infusion over 3 hours on day 1 of a 21-day cycle until disease progression or adverse effects prohibit further treatment
| Group | Source count |
|---|---|
| Ixabepilone | 34 |
Reported measurements
Source class 1
| Group | Value | Spread | Lower | Upper | Comment |
|---|---|---|---|---|---|
| Ixabepilone | 7.7 | Not reported | 4.0 | 11.7 | Not reported |
Complete source fields
- classes
- categories
- measurements
- group Id
- OG000
- lower Limit
- 4.0
- upper Limit
- 11.7
- value
- 7.7
- denoms
- counts
- group Id
- OG000
- value
- 34
- units
- Participants
- description
- Overall survival is defined as the duration of time from study entry to time of death or the date of last contact.
- dispersion Type
- 95% Confidence Interval
- groups
- description
- Ixabepilone administered at 40 mg/m2 IV infusion over 3 hours on day 1 of a 21-day cycle until disease progression or adverse effects prohibit further treatment
- id
- OG000
- title
- Ixabepilone
- param Type
- MEDIAN
- population Description
- Eligible and Treated Patients
- reporting Status
- POSTED
- time Frame
- From study entry to death or last contact, up to 5 years of follow-up.
- title
- Overall Survival
- type
- SECONDARY
- unit Of Measure
- months
Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f
Preserved source evidence · Not medical advice